Stock listing
Amplia Therapeutics Ltd.
Selected listing: ATX · ASX · AUD · AU
Amplia Therapeutics Ltd. (ASX:ATX), Health Technology. Latest release Aug 3, 2026: Amplia signs Collaboration and Supply Agreement with Lilly.
- Ticker
- ASX:ATX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
About Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd. (ASX: ATX) is a public company based in Australia, focusing on the development of innovative therapies for cancer and fibrotic diseases. The company aims to address significant unmet medical needs in the healthcare sector.
Latest news from Amplia Therapeutics Ltd.
Amplia signs Collaboration and Supply Agreement with Lilly
August 3, 2026
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
July 31, 2026
Amplia Announces Publication of New FAK Inhibitor Patent Application
July 9, 2026
Amplia Announces Appointment of Brett Carter to Board
July 7, 2026
Amplia Announces Changes to Board’s Leadership Roles
July 6, 2026
Research Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd. company profile
View the public company page for Amplia Therapeutics Ltd. on 6ix.
Amplia Therapeutics Ltd. news
Read company news and market updates connected to Amplia Therapeutics Ltd..
Amplia Therapeutics Ltd. investor events
Find investor webinars, events, and replay context for Amplia Therapeutics Ltd..